Insider Selling: Dyadic International (NASDAQ:DYAI) Major Shareholder Sells 26,340 Shares of Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 26,340 shares of the stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $2.43, for a total transaction of $64,006.20. Following the completion of the transaction, the insider directly owned 3,522,188 shares of the company’s stock, valued at $8,558,916.84. The trade was a 0.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Dyadic International Price Performance

DYAI stock opened at $0.94 on Monday. The stock has a market capitalization of $34.27 million, a PE ratio of -4.09 and a beta of 1.15. Dyadic International Inc. has a 52 week low of $0.65 and a 52 week high of $1.35. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. The firm has a 50 day moving average of $0.77 and a 200 day moving average of $0.83.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $1.11 million for the quarter, compared to analyst estimates of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. Sell-side analysts forecast that Dyadic International Inc. will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On Dyadic International

A number of institutional investors and hedge funds have recently modified their holdings of the company. Marathon Capital Management purchased a new stake in Dyadic International in the third quarter valued at approximately $41,000. Bank of America Corp DE increased its holdings in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares during the period. Landscape Capital Management L.L.C. purchased a new position in Dyadic International during the 3rd quarter worth approximately $190,000. Geode Capital Management LLC raised its position in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the last quarter. Finally, Apis Capital Advisors LLC acquired a new stake in Dyadic International during the 3rd quarter valued at approximately $1,817,000. Institutional investors and hedge funds own 27.95% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.